Vivid Genomics, Inc., a company focused on providing tools to improve clinical trials outcomes in neurodegenerative disease by identifying the right patients, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square.
SAN DIEGO /PRNewswire/ -- Vivid Genomics, Inc., a company focused on providing tools to improve clinical trials outcomes in neurodegenerative disease by identifying the right patients, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square. Dr. Julie Collens, CEO of Vivid Genomics, will be giving a presentation and meeting with investors. Event: Seed Showcase 2019 "We are pleased and honored to be selected as one of ten seed-stage companies to present during the Seed Showcase as part of the Biotech Showcase™," said Julie Collens, CEO of Vivid Genomics. The event takes place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference. For early-stage investors attending Biotech Showcase who wish to schedule a meeting with Vivid Genomics leadership, please contact info@vividgenomics.com. ABOUT VIVID GENOMICS Contacts
SOURCE Vivid Genomics |